ReviewFrontiers in bioengineering and biotechnology2023
Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance.
Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Bridging epigenetics and pharmacology through systematic reviews tailored to WBS methodology: the triangle decision-making model as a pioneering translational biological drug delivery system.Frontiers in medicine · 2025Pooled it
- A self-assembled protein nanocage as a universal influenza vaccine induces enhanced broadly cross-reactive immunity.Biomaterials · 2026Article
- Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory Diseases.Biomedicines · 2026Review
- A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.ACS materials letters · 2026Article
- Beyond inflammation: siRNA strategies for precision targeting in rheumatological disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Investigating the In Vitro Immunomodulatory Potential of Microparticulate β-L-Adenosine in Particulate Vaccine Candidates.Vaccines · 2026Article
- Nanoparticles in Thyroid Autoimmunity: Diagnostic and Therapeutic Applications.Journal of clinical medicine · 2026Review
- Nanoparticle-Based Tolerogenic Vaccines: Next-Generation Strategies for Autoimmune and Allergic Disease Therapies.Angewandte Chemie (International ed. in English) · 2026Review
- Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation.Small science · 2026Review
- Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering.Frontiers in immunology · 2026Review
- Advancements in nanomedicine for the therapeutic regulation of efferocytosis: opportunities and challenges.Theranostics · 2026Review
- Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- ROS-sensitive liposomal co-delivery of photosensitizer, factor Xa inhibitor, and PD-L1 blockade enhances photodynamic immunotherapy.Theranostics · 2026Article
- Nanomaterials in Targeted Immunotherapy for Chronic Spontaneous Urticaria: Focusing on Immune Cell Modulation and Precision Treatment.International journal of nanomedicine · 2026Review
- Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration.Journal of biomedical science · 2025Article
- Dendritic Cells: Orchestrators of Immune Responsiveness and Tolerance.Immunological reviews · 2025Review
- Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance.Journal of nanobiotechnology · 2025Review
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- Deinoxanthin-Enriched Extracellular Vesicles fromAntioxidants (Basel, Switzerland) · 2025Article
- Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy.Current gene therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) are the major specialized antigen-presenting cells (APCs), play a key role in initiating the body's immune response, maintain the balance of immunity. DCs can also induce immune tolerance by rendering effector T cells absent and anergy, and promoting the expansion of regulatory T cells. Induction of tolerogenic DCs has been proved to be a promising strategy for the treatment of autoimmune diseases, organ transplantation, and allergic diseases by various laboratory researches and clinical trials. The development of nano-delivery systems has led to advances
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.